Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 14/20 | 0.64 |
| ▸ | IKZF2 | Q9UKS7 | 8/20 | 0.51 |
| ▸ | CSNK1A1 | P48729 | 3/20 | 0.51 |
| ▸ | WIZ | O95785 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25010096 | 0.95 | CRBN (0.64) | CRBNIKZF2CSNK1A1WIZ | |
| SCHEMBL30270753 | 0.95 | CRBN (0.64) | CRBNIKZF2CSNK1A1WIZ | |
| SCHEMBL25010240 | 0.92 | CRBN (0.68) | CRBNIKZF2CSNK1A1WIZ | |
| SCHEMBL25010643 | 0.88 | CRBN (0.64) | CRBNIKZF2CSNK1A1WIZ | |
| SCHEMBL30270858 | 0.88 | CRBN (0.64) | CRBNIKZF2CSNK1A1WIZ | |
| SCHEMBL25010179 | 0.88 | CRBN (0.69) | CRBNIKZF2CSNK1A1 | |
| SCHEMBL25010306 | 0.87 | CRBN (0.63) | CRBNIKZF2CSNK1A1WIZ | |
| SCHEMBL30707579 | 0.87 | CRBN (0.63) | CRBNIKZF2CSNK1A1WIZ | |
| SCHEMBL25010335 | 0.87 | CRBN (0.63) | CRBNIKZF2CSNK1A1WIZ | |
| SCHEMBL25010092 | 0.87 | CRBN (0.59) | CRBNIKZF2CSNK1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4466260-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | Astrazeneca AB (SE) | 2024-11-27 | — | — | EP | disclosed |
| WO-2024238872-A2 | ISOINDOLINONE-GLUTARIMIDE ANTIBODY CONJUGATES, AND USES THEREOF | FIREFLY BIO, INC. (US) | 2024-11-21 | — | — | WO | disclosed |
| CN-118574821-A | Compounds and their use in the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2024-08-30 | — | — | CN | disclosed |
| EP-4308557-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | Arvinas Operations, Inc. (US) | 2024-01-24 | — | — | EP | disclosed |
| CN-117321046-A | Indazole-based compounds and related methods of use | 阿维纳斯企业公司 | 2023-12-29 | — | — | CN | disclosed |
| WO-2023139199-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2023-07-27 | — | — | WO | disclosed |
| WO-2023139199-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2023-07-27 | — | — | WO | disclosed |
| US-20230097358-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2023-03-30 | — | — | US | disclosed |
| US-20230045737-A1 | SUBSTITUTED ISOINDOLINONES AS MODULATORS OF CEREBLON-MEDIATED NEO-SUBSTRATE RECRUITMENT | VIVIDION THERAPEUTICS INC (US) | 2023-02-09 | — | — | US | disclosed |
| US-20230045737-A1 | SUBSTITUTED ISOINDOLINONES AS MODULATORS OF CEREBLON-MEDIATED NEO-SUBSTRATE RECRUITMENT | VIVIDION THERAPEUTICS INC (US) | 2023-02-09 | — | — | US | disclosed |
| WO-2022198112-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2022-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230097358-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | LRRK2, CRBN, MDM2 | CRBN 2/4885IKZF2 1680/4885CSNK1A1 257/4885 |
| US-20230045737-A1 | SUBSTITUTED ISOINDOLINONES AS MODULATORS OF CEREBLON-MEDIATED NEO-SUBSTRATE RECRUITMENT | CRBN, CLNS1A, CDR2 | CRBN 1/4885IKZF2 2339/4885CSNK1A1 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.